Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care
May 08, 2019 18:20 ET
|
NOVARTIS FINANCE S.A.
Xiidra (lifitegrast ophthalmic solution) 5% fits strategically within industry-leading USD 4.6 billion Novartis ophthalmic pharmaceutical portfolio, laying groundwork for front-of-the-eye pipeline...
Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded
April 24, 2019 01:00 ET
|
NOVARTIS FINANCE S.A.
Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2] Continuing operations net sales up 7% (cc[1], +2% USD) driven by...
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
March 26, 2019 19:35 ET
|
NOVARTIS FINANCE S.A.
Mayzent® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1] Up to 80% of patients...
Novartis plans for Alcon spin-off on April 9, 2019
March 22, 2019 02:00 ET
|
NOVARTIS FINANCE S.A.
Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange Alcon will seek effectiveness of Form 20-F registration statement from the US Securities and Exchange...
Novartis announces change in Sandoz leadership
March 14, 2019 02:15 ET
|
NOVARTIS FINANCE S.A.
Richard Francis, CEO Sandoz, to step down on March 31, 2019 Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz Basel, March 14, 2019 - Novartis announced...
Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off
February 25, 2019 17:55 ET
|
NOVARTIS FINANCE S.A.
Basel, February 25, 2019 - Novartis today published certain key financial information for the Alcon eye care business covering the full year 2018 ahead of a vote on the proposed 100% spin-off of...
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2018
January 30, 2019 10:16 ET
|
NOVARTIS FINANCE S.A.
As filed with the US Securities and Exchange Commission on January 30, 2019 ...
Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018
January 30, 2019 01:00 ET
|
NOVARTIS FINANCE S.A.
Full year net sales up 5% (cc[1], +6% USD) driven by strong performance of growth drivers: Pharmaceuticals BU grew 7% (cc) driven by Cosentyx USD 2.8 billion (+36% cc) and Entresto USD 1.0...
Novartis successfully completes acquisition of Endocyte
December 21, 2018 08:53 ET
|
NOVARTIS FINANCE S.A.
Adds 177Lu-PSMA-617, a potential first-in-class radioligand therapy in Phase III development for metastatic castration-resistant prostate cancer (mCRPC) Strengthens leadership in nuclear...
Novartis announces new CEO of Oncology Business Unit
December 20, 2018 01:00 ET
|
NOVARTIS FINANCE S.A.
Susanne Schaffert, Ph.D., President, AAA, an established Novartis executive, named new CEO, Novartis Oncology Basel, December 20, 2018 - Novartis announced today that Susanne Schaffert, Ph.D.,...